Olivia Vizier

The vice president of Innovation and New Technologies at Grifols provided perspective on the interim phase 2 findings of ABvac40, a vaccine in development for patients with Alzheimer disease.

Vittoria’s innovative Senza5 platform, with its unique CD5-targeting approach, aims to enhance the efficacy, safety, and speed of cell therapies.

This week, the Business of Biotech sits down with the legendary biotech investor Steve Gorlin, now CEO of CoRegen, for a conversation on his golden rules for picking winners.

Effector Therapeutics is working on selective translation regulator inhibitors (STRIs).

GigaGen, a subsidiary of Barcelona-based Grifols, aims to file an investigational new drug application next year, ahead of an initial trial of its recombinant polyclonal antibody therapy for chronic HBV infection

GigaGen, a subsidiary of Barcelona-based Grifols, aims to file an investigational new drug application next year, ahead of an initial trial of its recombinant polyclonal antibody therapy for chronic HBV infection.

The Phase II trial was not powered to show statistical significance on cognitive efficacy, but early Alzheimer’s patients treated with Araclon/Grifols’ anti-Aβ40 vaccine had slower decline by some measures.

The study is run by Mind Medicine, a biotech pharmaceutical company seeking approval for its proprietary form of LSD.

Reviva was founded in 2006 and has survived the double whammy of the GreatRecession and the Covid-19 pandemic.

At the core of CoRegen’s technology is the profound understanding of SRC-3, the master regulator of the Treg genome, first discovered in the lab of renowned molecular endocrinologist Bert O’Malley at the Baylor College of Medicine.

Revolo Biotherapeutics, the company developing ‘1104, is seeking to leverage the bacterium’s ability to “reset” the immune system. If further human trials pan out, maybe we’re headed toward a new generation of drugs derived from our interactions with microbes that inhabit our bodies.

Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains.

The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

At age 50, Alexandria Forbes founded MeiraGTx, a gene therapy company with six clinical programs and innovative technology to control genes with pills. (Gene-based medicine is typically administered via the injection of cells through a vector.)

Recce Pharmaceuticals, a biotechnology company focused on the global antibiotic-resistant patient population. This new class of synthetic antibiotics takes a broad-spectrum approach to kill bacterial infections, which continue to mutate, rendering existing antibiotics ineffective. The founding inventor of Recce is Dr. Graham Melrose, the grandfather of James, who has grown this idea into one of

Philipp Spycher has an extensive background in bioconjugation and ADCs. He obtained his master’s degree and Ph.D. from ETH Zurich in material science and protein engineering. During his post-doctoral work at Paul Scherrer Institute, he introduced the novel approach of using transglutaminases for antibody conjugation, which led to the discovery of what is now called

Meanwhile, Aphaia Pharma is also developing a promising drug candidate for weight loss, APH-012, with a focus on why L-cells – nutrient-sensing cells in the distal part of the intestine – in patients with metabolic disease are largely deprived from contact with food, as this leads to a lack of endocrine, neuroendocrine, and neuronal stim

Ambrx is the pioneer of an expanded genetic code technology platform for synthetic amino acid incorporation into proteins at any position, providing a unique

Xalud is using a non-viral DNA plasmid vector to restore homeostasis and treat pathologic inflammation within the immune system. Howard Rutman, M.D., MBA, Chief Medical Officer at Xalud Therapeutics

Switzerland-based Aphaia Pharma, in May launched its Phase II clinical trial of its daily glucose formulation, which is taken mixed with water. It curbs appetite by restoring the natural release of GLP-1 and other hormones, without causing nausea, Phase I data showed.

Tessera Therapeutics–a biotechnology startup based in Somerville, Massachusetts–followed with more modest flair: a simple banner, a speaker, and about 30 team members.

In MindMed’s LSD trial in Fort Collins, some groups are excluded from participation: pregnant women and people with a history of psychosis. That’s because the risks of using psychedelics in these populations are not fully understood.

The combination of large-scale biological datasets and developments in artificial intelligence (AI) has revolutionized our understanding and treatment of central nervous system (CNS) disorders.

A different approach, pursued by Zug, Switzerland-based Aphaia Pharma, is to reawaken nutrient-sensing cells in the distal gut that become less responsive in obesity

Elicio Therapeutics on Thursday said it closed a previously announced reverse merger

Reata is a biotech stock with a perfect Relative Strength Rating of 99, putting its 12-month price performance in the top 1% of all stocks, according to IBD Digital.

At the inception of eFFECTOR, one of the key considerations was that, to extend the duration of benefit of a given treatment, you have to contend with resistance. It had become clear that, even when using the most tightly targeted therapy or immunotherapy, resistance happens. I’ve spent about 15 years in the antiviral world working

Umoja wants to offer a solution. The biotech is working on ways to confront all the major limitations of CAR T-cell therapy—the lengthy, pricey manufacturing process and the poor efficacy against solid tumors—with therapies that reengineer a patient’s T cell

Since Dan O’Connor stepped in as CEO at Ambrx late last year, the company’s stock has rallied on the revival of a previously-shelved anti-HER2 ADC. It also raised $78 million and completed its ATM (at-the-market) offering. O’Connor is no stranger to overcoming adversity.

When I hosted Immunome President & CEO Purnanand Sarma, Ph.D. on episode 104 of the Business of Biotech podcast last summer, the company, like many emerging biotechs, was still wrapped up in rationalizing an application for its antibody technology in the battle against COVID-19.